Idhifa access in India: the CDSCO Rule 36 named-patient pathway
How patients in India access Idhifa (enasidenib) for IDH2-mutated relapsed or refractory acute myeloid leukemia when the medicine is not locally registered.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Idhifa in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
1. Quick orientation
Idhifa is the brand name for enasidenib, an oral once-daily small-molecule inhibitor of mutant isocitrate dehydrogenase-2 (IDH2). The US Food and Drug Administration granted regular approval on 1 August 2017 for adults with relapsed or refractory acute myeloid leukemia (AML) carrying a confirmed IDH2 mutation, as detected by an FDA-approved companion diagnostic. In India, Idhifa is not registered with the Central Drugs Standard Control Organization (CDSCO). Patients with biopsy-confirmed IDH2-mutated relapsed or refractory AML reach the medicine through Rule 36 of the Drugs and Cosmetics Rules 1945, administered by the office of the Drugs Controller General of India (DCGI), using Form 12A to apply for a Form 12B permit. The pathway is documented, accessible, and well used at India's tertiary specialty centres.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
2. Why India patients need Idhifa via the named-patient pathway
India has the deepest tertiary specialty hospital network of any Reserve Meds priority country and supplies a significant share of the world's generic medicines. Yet for a specific group of US-sourced specialty drugs, families in India still hit an access wall. Three patterns of access gap repeat: registered but not stocked, registered for a different indication, or not registered locally at all. Idhifa is firmly in the third pattern.
The European Medicines Agency application was withdrawn by Celgene in early 2020, after EMA review identified unresolved questions following the assessment cycle. Servier has not refiled centrally as of the most recent public disclosures, and CDSCO has no current registration of Idhifa. There is no local stock to dispense from a domestic pharmacy. The cumulative Indian patient population for IDH2-mutated relapsed or refractory AML in any one year is in the dozens rather than the hundreds, which sits below the threshold at which a commercial entity typically pursues local registration.
The clinical case for the Rule 36 pathway is unusually clean for Idhifa. Enasidenib is the only FDA-approved IDH2-selective inhibitor. Ivosidenib (Tibsovo) targets IDH1 and is not interchangeable. Venetoclax-based regimens and hypomethylating agents work through different mechanisms in different clinical settings. Once the IDH2 mutation is confirmed on the Abbott RealTime IDH2 Assay companion diagnostic or an equivalent CLIA-certified IDH2 next-generation sequencing panel, substitution to a locally registered alternative is not a clinical option. That fact carries the medical-necessity narrative for the Form 12A filing.
3. The CDSCO Rule 36 named-patient pathway for Idhifa
The legal foundation for personal import of unregistered medicines into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient.
The mechanism is documented and accessible. Form 12A is the application for a permit, made under the second proviso to Rule 36. Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported shall not exceed one hundred average doses per application.
For institutional Compassionate Use where the drug is not approved for marketing in India at all, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. This route is used when the drug is approved by a recognised reference authority such as the FDA for a life-threatening condition.
A complete CDSCO application for Idhifa typically includes:
- A clinical justification letter (diagnosis, IDH2 mutation status, prior therapies tried and failed, the specific reason this product is required)
- The treating hematologist's NMC registration number and state-council registration where required
- A patient identifier and supporting medical records
- Product details: Idhifa, enasidenib, Bristol Myers Squibb, 100 mg tablets, bottle of 30, quantity sufficient for the planned treatment cycle
- The dispensing facility's drug licence (hospital pharmacy, or specialty importer's wholesale licence)
- A chain-of-custody plan from the US specialty distributor to the dispensing pharmacy in India
The clinical-justification angle that matters most for Idhifa is biomarker confirmation. The treating hematologist documents the IDH2 mutation on the pathology report, states the relapse or refractory status against prior therapy (induction regimen, hypomethylating agent or venetoclax-based combination, allogeneic stem cell transplant where applicable), and explicitly notes that no IDH2-selective inhibitor is registered in India and that an IDH1 inhibitor is not substitutable for IDH2-mutated disease. CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing, and first-time or complex imports can take longer. We give you a written timeline estimate for your case before you commit.
4. Where Idhifa gets dispensed in India
Idhifa is an oral oncology product. It does not require infusion infrastructure, cold-chain storage, or cell-therapy capability. The dispensing requirement is a CDSCO-licensed hospital outpatient pharmacy or a licensed specialty importer, paired with an NMC-registered hematologist supervising the case.
For physicians at smaller institutions without an import pharmacy desk, the practical route is to work with one of the centres above, or with a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that handles the Form 12A filing and chain-of-custody documentation on behalf of the prescribing physician.
5. Real cost picture for Idhifa in India
Medicine price: quote on request. Every case gets a written custom quote before you commit. Three line items frame the case economics.
First, drug cost. Medicine price: quote on request. You get a written quote for your case before you commit.
Second, international logistics. Idhifa is a small-molecule oral tablet, room-temperature stable at 20 to 25 degrees Celsius with permitted excursions between 15 and 30 degrees Celsius. Medicine price: quote on request. You get a written quote for your case before you commit. No gel packs, no temperature loggers, no cold-chain quarantine risk.
Third, regulatory and coordination. India's Union Budget 2026-27 expanded the list of life-saving drugs and rare-disease drugs eligible for customs duty exemption, including a notable expansion in cancer medicines. GST on most life-saving medicines is 5 percent; the specific HSN code and exemption status of each Idhifa shipment is confirmed at the documentation stage. On the insurance side, private insurers assess named-patient imports case by case and none reimburses a Rule 36 personal import as a standard line item. CGHS provides for life-saving and anti-cancer medicines not in the standard formulary to be considered by an Expert Committee under the Special DG (DGHS) on a case-by-case basis, with stricter constraints on drugs not approved by DCGI. Cash-pay is the default posture; the documentation kit is structured so the patient or hospital can pursue reimbursement after the fact if the plan allows.
6. Typical timeline for Idhifa in India
CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing, and first-time or complex imports can take longer. We give you a written timeline estimate for your case before you commit. Idhifa is an ambient small-molecule product, which removes the cold-chain transit window from the timeline. and final verification and dispense at the hospital pharmacy. The FDA label specifies a minimum six-month trial of Idhifa because the differentiation mechanism produces delayed responses, with median time to first response of approximately 1.9 months and median time to best response of approximately 3.7 months, so supply cadence is planned for repeat shipments from the first case.
7. What your physician needs to provide
The clinical justification letter is the cornerstone of the Form 12A application for Idhifa. The treating Indian hematologist documents the patient's diagnosis as relapsed or refractory acute myeloid leukemia; states the IDH2 mutation status with explicit reference to the testing platform (Abbott RealTime IDH2 Assay or an equivalent CLIA-certified IDH2 next-generation sequencing panel) and the date of the pathology report; itemises prior lines of therapy with response and relapse documentation; states the reason a locally registered alternative is not suitable (the only FDA-approved IDH2-selective inhibitor is Idhifa; IDH1 inhibitors are not interchangeable for IDH2-mutated disease; venetoclax-based regimens, hypomethylating agents, and intensive chemotherapy work through different mechanisms and are options in different clinical settings); states the planned dosing regimen as 100 mg orally once daily continuous, taken at approximately the same time every day, with or without food, until disease progression or unacceptable toxicity, with a minimum six-month trial per the FDA label given the differentiation mechanism; and describes the monitoring plan, including vigilance for differentiation syndrome at every visit (the boxed warning), complete blood count and chemistries including bilirubin at baseline and at least monthly, QT interval monitoring where concomitant medication considerations apply, and management of leukocytosis with hydroxyurea without dose interruption when needed.
The letter is co-filed with the physician's NMC registration number and state-council registration where required, the dispensing facility's drug licence (hospital pharmacy or specialty importer wholesale licence), the requested pack and quantity (Idhifa 100 mg tablets, bottle of 30, typically a 30-day supply per bottle, capped at one hundred average doses per Form 12A application), and the chain-of-custody plan describing how the medicine will move from the US specialty distributor through the importer to the hospital pharmacy. Pharmacovigilance Programme of India (PvPI) reporting through the Indian Pharmacopoeia Commission applies for the duration of therapy and is the prescribing physician's obligation.
8. Common questions about Idhifa in India
Will a private insurer cover the cost? Each insurer assesses named-patient imports case by case. None of the major private insurers reimburse a Rule 36 personal import as a standard line item. Some have reimbursed full or partial drug cost when the underlying medicine is on their formulary and the import route was a stocking workaround. We supply the documentation that lets the insurer evaluate; the claim itself is filed by the patient or the hospital.
Will my CGHS or ESIC entitlement cover this? CGHS provides for life-saving and anti-cancer medicines not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS), case by case. Drugs not approved by the DCGI for use in India face a stricter Expert Committee review. ESIC's formulary is narrower. Neither scheme is structured for routine personal-import reimbursement; check eligibility with your CGHS Wellness Centre or the ESIC dispensary before assuming coverage.
Will my NMC-registered hematologist's letter be sufficient? Yes. Any Registered Medical Practitioner with a valid NMC registration number can support a Form 12A application.
Is the IDH2 mutation test available in India? Yes. Major Indian oncology pathology services run IDH2 mutation testing on CLIA-equivalent next-generation sequencing panels. Where a patient has had testing at a US, UK, or other reference laboratory, that pathology report is accepted in the Form 12A filing.
What is the safety profile I should know about? Idhifa carries a boxed warning for differentiation syndrome, which can be fatal if not recognised and treated. Symptoms include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain, peripheral oedema, and renal dysfunction. The boxed warning is managed through prescriber education and the label rather than through a restricted-distribution REMS programme.
Is Idhifa a controlled substance? No. Idhifa is not on the US DEA schedule and is not a controlled substance under Indian law. Narcotics Control Bureau coordination does not apply. The standard Rule 36 Form 12A and Form 12B permit is the operative framework.
9. Where Reserve Meds fits in Idhifa cases
Reserve Meds is a US-based digital health company. We do not replace your treating hematologist, the DCGI, the dispensing hospital pharmacy or licensed importer, or your insurer. What we do for an Idhifa case is verify eligibility within one business day; supply your physician's team with a documentation kit referencing the BMS prescribing information, the IDH2 biomarker requirements, and the Form 12A application format; align the US-side sourcing through a US-licensed pharmaceutical wholesale partner with the Indian dispensing pharmacy or specialty importer; coordinate the ambient courier shipment under chain-of-custody documentation; and provide a single point of contact across the case, regardless of how many Indian cities the family touches. The Reserve Meds operating model maps cleanly onto Idhifa: room-temperature handling, no infusion or reconstitution, biomarker-confirmed eligibility that simplifies the medical-necessity narrative for the DCGI filing, and a clearly absent local registration story. Standard NPP coordination applies.
10. Next step
If your Indian hematologist has confirmed IDH2-mutated relapsed or refractory AML and recommends Idhifa, start the request and we will reach out within one business day.
Reserved for you.